Template:KDRG: Difference between revisions
Jump to navigation
Jump to search
(Created page with "Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com]") |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[User:Kosar Doraghi|Kosar Doraghi, M.D.]][mailto:k.doraghi@yahoo.com] | [[User:Kosar Doraghi|Kosar Doraghi, M.D.]][mailto:k.doraghi@yahoo.com] | ||
=Kosar Doraghi, M.D.= | |||
==Current Position== | |||
'''Associate Editor-in-Chief,''' Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar | |||
==Pages Authored/Co-authored/Collaborated== | |||
<div style="-moz-column-count:8; column-count:3;"> | |||
#[[NEXOBRID]] | |||
#[[RELYVRIO]] | |||
#[[Deucravacitinib]] | |||
#[[Ublituximab-xiiy]] | |||
#[[futibatinib]] | |||
#[[Tapinarof]] | |||
#[[Spevigo- spesolimab-sbz]] | |||
#[[Vericiguat]] | |||
#[[Dasiglucagon]] | |||
#[[Ponesimod]] | |||
#[[Lasmiditan]] | |||
#[[Nirogacestat]] | |||
#[[Nedosiran]] | |||
#[[Ryzneuta]] | |||
#[[Endocarditis overview]] | |||
#[[Sparsentan]] | |||
#[[BRENZAVVY- bexagliflozin]] | |||
#[[New GOLD 2024 Recommendation for Vaccination of COPD Patients]] | |||
#[[Nirsevimab]] | |||
#[[Xacduro- sulbactam and durlobactam]] | |||
#[[EXXUA(gepirone)]] | |||
Revision as of 21:38, 8 May 2024
Kosar Doraghi, M.D.
Current Position
Associate Editor-in-Chief, Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar
Pages Authored/Co-authored/Collaborated
- NEXOBRID
- RELYVRIO
- Deucravacitinib
- Ublituximab-xiiy
- futibatinib
- Tapinarof
- Spevigo- spesolimab-sbz
- Vericiguat
- Dasiglucagon
- Ponesimod
- Lasmiditan
- Nirogacestat
- Nedosiran
- Ryzneuta
- Endocarditis overview
- Sparsentan
- BRENZAVVY- bexagliflozin
- New GOLD 2024 Recommendation for Vaccination of COPD Patients
- Nirsevimab
- Xacduro- sulbactam and durlobactam
- EXXUA(gepirone)